Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT]

NCT00626015 is registered in ClinicalTrials.gov with John Sampson as lead sponsor.

NCT NCT00626015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT]
Lead sponsor
John Sampson
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
February 28, 2013
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasms of brain